Obviously the reward associated with clinical is huge, but that's because the risk is also equally huge! Regarding "put in the time and effort and know what you're doing", I have to say, the fact that stock loses 70% of the value means no one can actually predict these events!

$eltx longer trial doesnt mean vaxxxxxxxxxx is working 🧐😩🤯🫨😶‍🌫️🥶🥵

You think I’m a pussy bro @IBKR

I think LOs are underrated. Bespoke and tailored research process where you can spend weeks, days, months even on a single name. Helps to filter out all the day to day noise happening in markets when you have the freedom of deep research and long investment horizons.

Lucky for you they didn’t get to see your bad call on $SLS materialize yet. Congrats!

Spent the last month teaching myself biotech from scratch. I’m not a doctor. But I know how to read probability and I know when a market is mispricing a binary event. $SLS is the most asymmetric setup I’ve ever come across. Thread.

I have been quietly attending Soapland for years in the name of Japanese equity research, and last month it delivered one of the cleanest edges I’ve ever found on a cheap Japanese stock. I walked into a quiet spot in Yoshiwara for a standard ¥48,000 session. The therapist was sharp, the kind who’d spent the whole week scrubbing exhausted salarymen from a sleepy industrial supplier in Gifu Prefecture. Between the legendary bubble technique and the special rinse, she started venting about this one stubborn client — a 72-year-old president who still refused to retire. Domestic orders were softening, the company was sitting on a mountain of cash it barely deployed, but the old man wouldn’t budge on costs or succession. She named the exact supplier, the margin pressure they were feeling, and how the whole operation was running like it was still 1995. I listened, asked a few gentle follow-ups, walked out, ran the numbers that night. The company was trading at 4x earnings with a fortress balance sheet, net cash covering half the market cap, and almost no analyst coverage. I bought 0.9% of the obscure forklift-spring manufacturer whose name I still can’t pronounce. Six weeks later it rerated 38%. That’s the thing about corporate Japan. In public, everything is polite theater and hierarchical silence. But in those private rooms where ranks dissolve in soap suds and tired section chiefs finally drop their armor, the real unfiltered color leaks out — overtime realities, capex delays, succession drama, inventory builds. The kind of early signals that never make it into Nomura notes or IR decks. I’ve cross-checked enough of these bubble briefings against later earnings to know the edge is real. The math doesn’t lie, and neither do the bubbles. This is how you still find genuine information asymmetry in 2026: by going where the salarymen actually talk.